Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/101862
DC FieldValueLanguage
dc.contributor.authorReis, A . J.-
dc.contributor.authorAlves, C.-
dc.contributor.authorFurtado, S.-
dc.contributor.authorFerreira, J.-
dc.contributor.authorDrummond, M.-
dc.contributor.authorRobalo-Cordeiro, C.-
dc.date.accessioned2022-09-19T08:14:23Z-
dc.date.available2022-09-19T08:14:23Z-
dc.date.issued2018-
dc.identifier.issn25310437pt
dc.identifier.urihttps://hdl.handle.net/10316/101862-
dc.description.abstractChronic Obstructive Pulmonary Disease (COPD) is a serious pulmonary condition. Many patients experience exacerbations and some require Emergency Room visits and hospitalization. In Portugal, hospitalizations due to COPD between 2009 and 2016 decreased by 8%, but they still represented 8049 hospitalized patients in 2016. Appropriate management of COPD exacerbations presents a clinical challenge and, in order to guide therapy, it is important to identify the underlying cause; however, this is not possible in about a third of severe COPD exacerbations. There are several diagnostic tools that can be used to assess an exacerbation and its severity, which will in turn guide treatment, and prognostic scores should be used to predict the risk of future exacerbations. After an exacerbation is appropriately managed, a suitable discharge plan should be prepared. This should generally include reclassification of the patient according to GOLD criteria, optimization of pharmacological therapy, management of comorbidities, patient (or caregiver) education on the correct use of medications, referral to a Pulmonology Outpatient Clinic, if they are not already attending one, and a smoking cessation and respiratory rehabilitation program. In this paper, we will focus on the pharmacological strategies for the management of COPD exacerbations, risk stratification and a hospital discharge plan proposal.pt
dc.language.isoengpt
dc.relationNovartis Portugalpt
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt
dc.subjectCOPDpt
dc.subjectExacerbationpt
dc.subjectHospitalizationpt
dc.subjectManagementpt
dc.subjectDischargept
dc.subject.meshAftercarept
dc.subject.meshDisease Progressionpt
dc.subject.meshHumanspt
dc.subject.meshPulmonary Disease, Chronic Obstructivept
dc.subject.meshSeverity of Illness Indexpt
dc.subject.meshPatient Dischargept
dc.titleCOPD exacerbations: management and hospital dischargept
dc.typearticle-
degois.publication.firstPage345pt
degois.publication.lastPage350pt
degois.publication.issue6pt
degois.publication.titlePulmonologypt
dc.peerreviewedyespt
dc.identifier.doi10.1016/j.pulmoe.2018.06.006pt
degois.publication.volume24pt
dc.date.embargo2018-01-01*
uc.date.periodoEmbargo0pt
item.languageiso639-1en-
item.fulltextCom Texto completo-
item.grantfulltextopen-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypearticle-
item.cerifentitytypePublications-
crisitem.project.grantnoA Novartis foca a sua atividade em duas divisões com poder de inovação e dimensão global: farmacêutica e medicamentos genéricos e biossimilares- Portugal-
crisitem.author.researchunitiNOVA4Health - Programme in Translational Medicine (iBET, CEDOC/FCM, IPOLFG and ITQB)-
crisitem.author.orcid0000-0002-8264-3856-
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais
Files in This Item:
File Description SizeFormat
1-s2.0-S2531043718301077-main.pdf692.01 kBAdobe PDFView/Open
Show simple item record

SCOPUSTM   
Citations

15
checked on Nov 4, 2024

WEB OF SCIENCETM
Citations

17
checked on Nov 2, 2024

Page view(s)

123
checked on Nov 5, 2024

Download(s)

77
checked on Nov 5, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons